Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Revenue (2021 - 2024)

Amylyx Pharmaceuticals has reported Revenue over the past 4 years, most recently at -$636000.0 for Q4 2024.

  • Quarterly results put Revenue at -$636000.0 for Q4 2024, down 100.84% from a year ago — trailing twelve months through Sep 2025 was -$636000.0 (down 100.38% YoY), and the annual figure for FY2024 was $87.4 million, down 77.05%.
  • Revenue for Q4 2024 was -$636000.0 at Amylyx Pharmaceuticals, down from $416000.0 in the prior quarter.
  • Over the last five years, Revenue for AMLX hit a ceiling of $102.7 million in Q3 2023 and a floor of -$636000.0 in Q4 2024.
  • Median Revenue over the past 4 years was $26.6 million (2022), compared with a mean of $42.3 million.
  • Biggest five-year swings in Revenue: soared 18673.86% in 2023 and later tumbled 100.84% in 2024.
  • Amylyx Pharmaceuticals' Revenue stood at $285000.0 in 2021, then soared by 9218.25% to $26.6 million in 2022, then surged by 186.04% to $76.0 million in 2023, then tumbled by 100.84% to -$636000.0 in 2024.
  • The last three reported values for Revenue were -$636000.0 (Q4 2024), $416000.0 (Q3 2024), and $1.0 million (Q2 2024) per Business Quant data.